138 related articles for article (PubMed ID: 11251188)
1. Decreased tissue plasminogen activator and increased plasminogen activator inhibitors and increased activator protein-1 and specific promoter 1 are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine.
Pelayo BA; Fu YM; Meadows GG
Int J Oncol; 2001 Apr; 18(4):877-83. PubMed ID: 11251188
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of B16BL6 melanoma invasion by tyrosine and phenylalanine deprivation is associated with decreased secretion of plasminogen activators and increased plasminogen activator inhibitors.
Pelayo BA; Fu YM; Meadows GG
Clin Exp Metastasis; 1999; 17(10):841-8. PubMed ID: 11089882
[TBL] [Abstract][Full Text] [Related]
3. Attachment, invasion, chemotaxis, and proteinase expression of B16-BL6 melanoma cells exhibiting a low metastatic phenotype after exposure to dietary restriction of tyrosine and phenylalanine.
Uhlenkott CE; Huijzer JC; Cardeiro DJ; Elstad CA; Meadows GG
Clin Exp Metastasis; 1996 Mar; 14(2):125-37. PubMed ID: 8605726
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Meissauer A; Kramer MD; Hofmann M; Erkell LJ; Jacob E; Schirrmacher V; Brunner G
Exp Cell Res; 1991 Feb; 192(2):453-9. PubMed ID: 1899072
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase-dependent apoptosis of melanoma induced by tyrosine and phenylalanine deficiency.
Fu YM; Yu ZX; Pelayo BA; Ferrans VJ; Meadows GG
Cancer Res; 1999 Feb; 59(3):758-65. PubMed ID: 9973229
[TBL] [Abstract][Full Text] [Related]
6. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
7. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
8. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
9. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
10. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
[TBL] [Abstract][Full Text] [Related]
11. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity.
Tsuboi R; Rifkin DB
Int J Cancer; 1990 Jul; 46(1):56-60. PubMed ID: 2142142
[TBL] [Abstract][Full Text] [Related]
12. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Buø L; Bjørnland K; Karlsrud TS; Kvale D; Kjønniksen I; Fodstad O; Brandtzaeg P; Johansen HT; Aasen AO
Anticancer Res; 1994; 14(6B):2445-51. PubMed ID: 7872665
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.
de Serrano VS; Castellino FJ
J Biol Chem; 1990 Jun; 265(18):10473-8. PubMed ID: 2113057
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
15. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
16. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator system in human breast cancer.
Sumiyoshi K; Serizawa K; Urano T; Takada Y; Takada A; Baba S
Int J Cancer; 1992 Feb; 50(3):345-8. PubMed ID: 1735602
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator and its receptor during ovarian follicular development.
Li M; Karakji EG; Xing R; Fryer JN; Carnegie JA; Rabbani SA; Tsang BK
Endocrinology; 1997 Jul; 138(7):2790-9. PubMed ID: 9202219
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA.
Fukumoto S; Allan EH; Yee JA; Gelehrter TD; Martin TJ
J Cell Physiol; 1992 Aug; 152(2):346-55. PubMed ID: 1322417
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]